7th Mar 2019 10:30
LONDON (Alliance News) - OKYO Pharma Ltd on Thursday said it will present preclinical results demonstrating anti-inflammatory activity and the potential of OKYO-0101 in the treatment of dry eye.
OKYO Pharma shares rose 15% to 1.32 pence on Thursday morning.
The biotechnology firm said treatment with OKYO-0101 reduced "significantly" the increase in corneal permeability due to dry eye. Furthermore, the product normalised the dry eye induced loss of goblet cell density.
Rabbit ocular tolerance test using OKYO-0101 showed "no adverse signs" such as inflammation, chemosis or hyperemia and signs of local irritation, the company added.
Related Shares:
OKYO.L